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INTRODUCTION: 
For oral sustained or prolonged-release dosage forms, 
multip le units are more advantageous than single units 
because they disperse widely and uniformly along the 
gastrointestinal tract and could lessen intra- and inter-
subject variability. Gastric-retentive systems, mult iple 
units, may have the advantage of avoiding all- or –nothing 
emptying, and increase the probability that some of the 
dosage form will remain in the stomach 
1
. Approaches 
devising multiple unit floating systems include mult iple 
unit HBS, polycarbonate microspheres 
2
, alginate beads 
3
, 
charged ion exchange resins with bicarbonate 
4,5,6
, air 
compartment multip le unit systems, coated granules with a 
dual effervescent layer 
7
 and emulsion  solvent diffusion 
8,9,10
. 
There are various approaches in delivering substances to 
the target site in a controlled release fashion via oral route. 
One such approach is using polymeric hollow microsphere 
as carrier for drugs. Hollow microspheres are known as the 
microballoonsdue to their low-density core 
11
. 
Microballoons based drug delivery systems have received 
considerable attention in recent years. The most important 
characteristics of microballoons are microphase separation 
morphology, which endows it with a controllable 
variability in degradation rate and also drug release.
12,13
 
Multiple unit systems such as microballoons capable of 
floating on the gastric fluid have the advantage that they 
are not subjected to “all or nothing” gastric emptying 
nature of single unit systems. Drug loaded polymeric 
microballoons and ion-exchange beads capable of floating 
on the gastric flu ids have therefore been examined as FDF. 
Norfloxacin is a potent antibacterial agent having very 
broad spectrum of its activity. It acts by inhibiting DNA 
Gyrase and hence it is specific bacterial DNA Gyrase  
 
blocker, thus it inhibits the synthesis of DNA in bacteria 
leading to its rapid  lyses
14
. Owing to the variable transit 
time in gastro intestinal tract of all dosage forms, it could  
not be ascertained to localize a dosage form at the site of 
maximum absorption of a drug. So it was proposed to 
prepare floating microballoons of norfloxacin to localize 
the drug at its site of maximum absorption. 
For the development of floating microballoons of 
norfloxacin, a combination of polymer Eudragit RS 100 
and Eudragit L 100 was selected. These polymers are 
comes under the category of polymethacrylates. Anionic 
acrylic polymer Eudrag it L 100 is insoluble in acid media 
i.e. resistant to gastric fluid, and dissolves only in the 
neutral to weakly alkaline medium of the small intes tine. 
Permeable acrylic po lymer Eudrag it RS 100 is water 
insoluble over the entire pH range, but swells in digestive 
flu ids independently of pH. In the swollen state it is 
permeable to water and dissolved actives
15
.   
In this study, an emulsion solvent diffusion/evaporation 
technique was used to prepare a floating controlled-release 
system for norfloxacin and the influence of several factors 
on various physical characteristics, including the particle 
size, drug loading , dissolution and floating properties of 
the resulting microspheres, were investigated. 
MATERIAL AND METHOD: 
MATERIAL: The gift sample of Norfloxacin was 
obtained from Aurochem Pharma. Pvt. Ltd. Mumbai. 
Eudragit L-100 and Eudragit  RS-100 were obtained as a 
gift sample from pharmachem, Gujrat. Rest of the 
chemicals was of analytical grade. 
 
ABSTRACT 
The present study involves preparation and evaluation of floating microballoons of norfloxacin for improving the 
bioavailability by prolongation of gastric residence time. Norfloxacin, a sparingly water soluble drug, was selected 
and microballoons were prepared by emulsion solvent diffusion method using Eudragit L-100 and Eudragit RS-100 
in ethyl alcohol and dichloromethane organic solvent system. The formation of a sphere and hollow within the 
sphere was confirmed through SEM studies. The percentage of drug entrapment  and recovery was found to be 75- 
80%. The micromeritic properties indicated better flowability and packability of the spheres. The Buoyancy test 
showed good floatability of norfloxacin microballoons in the simulated gastric fluid for more than 12 h. In vitro 
dissolution profile showed prolonged release of drug from the formulations. Thus microballoons of norfloxacin 
with acrylic polymers prepared by emulsion solvent diffusion proves to be an ideal novel floating dosage form that 
is adaptable to any intragastric condition for controlled drug delivery and enhanced bioavailability. 
Keywords: norfloxacin, hollow microspheres, acrylic polymers, evaluation 
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METHOD: 
Microballoons with an internal hollow structure were 
prepared by solvent diffusion-evaporation method
16
. Equal 
quantities of two polymers i.e. Eudragit L-100 and 
Eudragit RS-100 were dissolved in ethanol, followed by 
the addition of isopropanol and dichloromethane. Then 
drug was homogeneously dispersed in this polymer 
solution. This polymer solution was slowly introduced into 
poly-vinyl alcohol (PVA) aqueous solution with stirring 
using a mechanical stirrer equipped with a propeller. The 
solution was stirred for 1 hour and microballoons were 
collected by filtrat ion and washed 3 times with distilled  
water, dried at 40
o
C and kept in desiccators
17
. 
CHARACTERIZATION OF NORFLOXACIN 
MICROBALLOONS
18, 19, 20
 
1. Morphology: 
The surface morphology of microballoons selected on the 
basis of optical microscopy was visualized by scanning 
electron microscopy. The samples for SEM were prepared  
by lightly sprinkling the microballoons powder on a 
double adhesive tape which s tuck to an aluminum stub. 
The stubs were then coated with gold to a thickness of 
about 300
o
A using a sputter coater. These samples were 
than randomly scanned and photomicrographs were taken 
which are shown in Fig. 1. 
Figure 1: SEM of floating microballoons (2.39 K X) 
 
2.  Percent yield of microballoons 
The prepared microballoons were collected and weighed. 
The weight of microballoons was divided by the total 
weight of all the non-volatile components used for the 
preparation of the microballoons. 
% yield = weight of microballoons collected / wt. of all 
non-volatile components used for the preparation x 100 
Table 1: Effect of polymer: polymer ratio (Eudrag it L 100: Eudragit RS 100) 
S.No. Formulation Code Eudragit L 100: Eudragit RS 100 % yield 
1 OESTDP1 1:0 90.1 
2 OESTDP2 0:1 88.2 
3 OESTDP3 1:2 89.2 
4 OESTDP4 1:3 86.3 
5 OESTDP5 2:3 87.7 
6 OESTDP6 3:2 89.6 
7 OESTDP7 3:1 90.0 
 8 OESTDP8 2:1 89.8 
 
Figure 2: % y ield of microspheres at different polymer: polymer rat io (Eudragit L100: Eudrag it RS 100)  
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3. Percentage drug loading efficiency: The prepared 
microballoons were digested in minimum quantity of 
ethanol (95%), and then diluted with acetate buffer 
(pH 4.6) up to 10 ml. The digested homogenate was 
centrifuged at 3000 rpm for 3 minutes and the 
supernatant after suitable dilution was assayed for 
norfloxacin spectrophotometrically.  
The percentage drug entrapment is calculated from the 
equation given below. 
% Drug entrapped = Amount of drug in the 
microballoons (actual content)/ Amount of drug used in 
formulation (theoretical content) x 100
Table 2:  Drug entrapment values at different polymer ratio (Eudrag it L 100: Eudrag it RS100)  
S. No. Formulation Code Eudragit L 100 :  
Eudragit RS 100 
           % entrapped drug 
1 OESTDP1 1:0 77.9 
2 OESTDP2 0:1 71.8 
3 OESTDP3 1:2 73.8 
4 OESTDP4 1:3 73.2 
5 OESTDP5 2:3 74.4 
6 OESTDP6 3:2 75.2 
7 OESTDP7 3:1 77.4 
8 OESTDP8 2:1 75.2 
 
Figure 3:  % drug entrapment at different polymer: po lymer ratio (Eudragit L100: Eudragit RS100) 
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4. Determination of physical parameters: Prepared microballoons were evaluated for their physical properties like density, 
porosity and angle of repose. 
Table 3: Density and porosity of different formulations  
S. No. Formulation Code Density % Porosity Angle of repose (o) 
1 OESTDP1 0.719 47.8 29.4 
2 OESTDP2 0.834 60.5 32.0 
3 OESTDP3 0.802 57.9 31.2 
4 OESTDP4 0.825 59.6 31.6 
5 OESTDP5 0.787 56.2 30.8 
6 OESTDP6 0.742 51.3 30.5 
7 OESTDP7 0.726 48.9 29.7 
8 OESTDP8 0.738 50.4 30.1 
 
1. In vitro floating behavior:  
The floating test of the microballoons was carried out 
using the Dissolution test Apparatus method II specified in  
the USP XX
21
. The unloaded microballoons (800 mg) were 
spread over the surface of the simulated gastric flu id pH 
1.2 (900 ml, 37 ± 0.5
o
C) which was agited by a paddle 
rotated at 100 rpm. Dissolution test solution SGF (pH 1.2) 
containing Tween 20 (0.02% w/v) was used as dispersion 
medium to simulate gastric fluid. After ag itation for a 
previously determined interval, the microballoons that 
were floating and the ones that settled to the bottom of the 
flask were recovered separately.  
After drying, the fraction of the microballoons was 
weighed; the % buoyancy of the             microballoons was 
calculated by the following equation: 
Percent buoyancy = Qf  / (Qf  + Qs) × 100 
Where, Qs is the weight of the settled microballoons, Q f is 
weight of microballoons that were floating. The results are 
shown in Table 4 and graphically presented in Fig. 4. 
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Table 4: Table 4: Percent buoyancy of different unloaded microballoons formulat ions in  SGF (pH 1.2) at 37 ± 0.5
o
C 
S.No. Formulation  
    Code 
           % Buoyancy at different time intervals 
                                    (hour ) 
1 2 3 4 5 6 7        24 
1 OESTDP1 97.1 92.8 88.0 83.6 80.1 79.8 76.7 60.9 
2 OESTDP2 92.1 89.2 85.3 83.8 78.2 74.1 69.8 51.8 
3 OESTDP3 95.4 92.7 88.7 84.7 79.9 77.1 71.3 54.1 
4 OESTDP4 95.0 90.3 88.2 84.3 79.6 75.2 70.0 52.6 
5 OESTDP5 95.6 91.7 90.2 84.9 80.1 78.2 71.9 54.8 
6 OESTDP6 96.0 91.7 89.8 84.7 80.9 79.3 72.8 58.7 
7 OESTDP7 93.6 92.7 90.2 86.2 82.1 79.7 76.3 60.1 
8 OESTDP8 96.2 92.3 89.3 84.4 81.3 79.2 75.1 59.4 
 
Figure 4: % buoyancy of different unloaded formulations in SGF at 37 ± 1
o
C      
 
1. In vi tro drug release:  
The optimized nine formulations of norfloxacin  
microspheres e.g. OESTDP1……OESTDP8 were selected 
for the in vit ro drug release studies. The drug release 
studies of microballoons were carried out in Dissolution 
Test Apparatus II USP XX by the paddle method. 
Microballoons equivalent to 800 mg of norfloxacin were 
gently spread over the surface of 900 ml of d issolution 
medium (SGF pH 1.2,) as specified in the Indian  
pharmacopoeia 2007. 
                The paddle was rotated at 100 rpm and the temperature of 
dissolution medium was thermostatically controlled at 37 ± 
0.5
o
C. The samples were withdrawn at a suitable intervals 
of time from the dissolution vessel and were assayed after 
appropriate dilution spectrophotometrically at 278 nm in  
acidic medium for norfloxacin using Shimadzu 1700 (UV-
Visib le spectrophotometer)  
Table 5: In vitro d rug release profile o f norfloxacin from optimized microballoons in SGF (pH 1.2) at λ max 278 nm 
S. No. Formulation Code % cumulative drug release (hour ) 
1 2 3 4 5 6 7 24 
1 OESTDP1 6.1 8.2 9.8 10.3 11.1 11.6 12.2 21.3 
2 OESTDP2 11.6 25.9 37.8 46.2 54.3 61.3 64.4 93.2 
3 OESTDP3 7.6 16.9 25.7 36.8 43.9 51.4 54.8 91.3 
4 OESTDP4 8.0 20.2 32.9 41.3 48.7 56.2 60.1 92.3 
5 OESTDP5 7.4 15.8 23.2 30.1 37.3 42.6 46.4 90.3 
6 OESTDP6 6.8 13.6 18.4 23.1 29.0 32.1 36.2 76.9 
7 OESTDP7 6.6 11.8 14.9 20.1 22.8 26.0 29.7 56.2 
8 OESTDP8 6.7 12.3 15.2 20.8 24.7 28.6 31.5 65.9 
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Figure 5:   In vit ro drug release profile of norfloxacin from optimized microballoons in SGF (pH 1.2) at λ max 278 nm. 
 
 
RES ULTS AND DISCUSS ION:  
The floating microballoons were prepared by emulsion 
solvent diffusion evaporation method using combination of 
polymers (Eudrag it L 100 and Eudragit RS 100). 
Formation of a stable o/w emulsion at the initial stage and 
the precipitation of the polymer at the surface of the 
dispersed droplet were the key factors in preparing 
desirable floating microballoons. The counter diffusion of 
ethanol and water through the interface between the 
emulsion droplet and the aqueous medium reduced the 
solubility of the polymer at the interface with the droplet 
inducing precipitation of the polymer on the surface of the 
emulsion droplet. The dispersed droplet of the emulsion 
was enclosed with a film like shell of the polymer. Based 
on the results from the o/w solvent diffusion method, the 
solvent composition of dichloromethane: ethanol: 
isopropanol (5: 8: 2) was considered and used in 
preparations. 
Formulat ions are optimized fo r different process variables 
like So lvent ratio (dichloromethane: ethanol: isopropanol), 
drug-polymer ratio, Emulsifier concentration, temp. and 
stirring speed which are represented in the article as 
O,D,E,T and S respectively. 
The scanning electron microphotograph clearly indicates  
that the microspheres are spherical in shape and there is a 
formation of hollow cavity in the sphere (Fig 1). It was 
clear that the solubility of the drug will determine the 
preferential location of the drug among the solvents used. 
Norfloxacin being water insoluble has a high entrapment 
in the microballoons. One more factor that has a high 
entrapment of drug was the proportion of Eudragit RS 100 
in the polymer phase. As the proportion of Eudragit RS 
100 was increased, the entrapment efficiency decreased 
owing to high porous nature of the polymer.  
It was found that most of the microballoons were still 
floatable even after 24 hours of testing because of their 
low density and owing to the internal voids being 
completely conserved during the test. This finding 
indicated that the enteric property of the microballoons 
shell might be advantageous in prolonging the residence 
time of microballoons in the stomach, since dissolution 
and disruption of the microballoons could be prevented. 
A combination of polymer was used for the current study 
to design a perfect gastro retentive delivery system which  
released most of the drug in upper part of gastrointestinal 
tract. As the amount of Eudragit RS 100 used in the 
preparation was increased the release of the drug was also 
increased. It may be concluded from this in vitro drug 
release study that the release rate can be controlled by 
varying the polymer: polymer rat io and the dosage form 
could be designed to give the release in a controlled 
fashion at the desired site. As for norfloxacin, the site of 
absorption is upper GI tract, the formulation OESTDP3 and 
OESTDP5 can serve the needs of a controlled release in 
upper GIT. 
The data obtained from in vitro dissolution studies were 
fitted into Zero order, First order and Kors meyer-Peppas 
models. Regression analysis suggests that the release of 
drug from microballoons followed non-Fickian diffusion 
mechanis m. 
CONCLUS ION:   
The microballoons of norfloxacin prepared by emulsion-
solvent diffusion method exhib ited excellent in vitro 
buoyancy and the drug release was sufficiently sustained 
with non-Fickian transport of drug from the microballoons. 
Hence the floating hollow microspheres  of norfloxacin  
prepared with acrylic polymers may provide a convenient 
dosage form for ach ieving better floating behavior and 
drug release. 
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